AtriCure (ATRC) Q3 2023: Open Ablation Drives 20% Franchise Growth as R&D Outpaces SG&A
Open ablation and pain management franchises powered AtriCure’s double-digit growth, while R&D investment continues to accelerate ahead of SG&A. Management’s conviction in underpenetrated markets and workflow innovation supports a bullish multi-year outlook, yet margin expansion will require careful balancing of clinical trial and product pipeline spend as new launches approach. Execution focus remains on volume-driven growth, workflow efficiency, and clinical evidence to unlock broader adoption.
Summary
- Volume-Driven Expansion: Core franchises fueled growth as Encompass Clamp and Cryosphere adoption deepened in underpenetrated markets.
- Clinical Pipeline Acceleration: R&D spend rose sharply, signaling commitment to long-term clinical trial and product innovation.
- Margin Leverage Watchpoint: Sustained profitability will hinge on balancing operating leverage with elevated R&D and commercial investment.
Business Overview
AtriCure develops and commercializes medical devices for the treatment of atrial fibrillation (AFib), left atrial appendage (LAA) management, and post-operative pain management. The company’s revenue is generated from three main franchises: open ablation (devices for cardiac surgery), appendage management (LAA closure products), and pain management (cryoablation for post-surgical pain). Open ablation and appendage management are the largest contributors, with pain management as a fast-rising segment. Sales are split between the U.S. and international markets, with a diversified product portfolio and a growing clinical trial pipeline.
Performance Analysis
AtriCure delivered robust 18% year-over-year revenue growth in Q3, led by strong performance in open ablation and pain management. The Encompass Clamp, open ablation device, maintained momentum with sales exceeding $10 million for the second straight quarter, driving 20% growth in the open ablation franchise. Appendage management accounted for 40% of revenue and grew 18% year-over-year, propelled by the AtriClip Flex V device. Pain management, though smaller, posted 24% growth as Cryosphere probe adoption accelerated globally.
Gross margin improved by 110 basis points to 75.2%, reflecting production efficiencies, though partially offset by geographic and product mix. Operating expenses increased 13%, with research and development (R&D) spend up 34%, far outpacing the 8% rise in selling, general, and administrative (SG&A) costs. This reflects the company’s focus on clinical trial enrollment, notably the LEAPS trial, and next-generation product development. Adjusted EBITDA turned positive, marking a shift toward sustainable profitability, while net loss per share narrowed year-over-year.
- Encompass Clamp Penetration: Volume growth, not price, was the primary driver in open ablation, with significant runway in underpenetrated CABG procedures.
- International Expansion: International revenue grew 23%, fueled by adoption in Europe and Asia Pacific, with favorable currency tailwind.
- Pain Management Upside: Cryosphere probe adoption remains below 15% penetration, indicating substantial long-term growth potential.
Sequential revenue dipped 2.6% due to seasonality, but management expects core franchises to lead Q4 growth. Cash burn was modest, tied to manufacturing and inventory expansion, with a strong $133 million cash position.
Executive Commentary
"Growth from the Encompass Clamp remains incredibly strong. Our Encompass Clamp leverages the proven technology of our Synergy ablation system to provide simpler and faster ablations in open heart procedures. Physician feedback is exceptional, with many underscoring the efficiency and ease of use of the device."
Mike Carroll, President and CEO
"The increase in research and development expenses was 34% year over year, well outpacing the 8% increase in selling general and administrative costs. Research and development expenses reflect expanding activity and faster-than-expected enrollment in our LEAPS clinical trial, as well as progress in several new product development projects."
Angie Wyrick, Chief Financial Officer
Strategic Positioning
1. Volume-Led Growth in Underserved Markets
Open ablation and pain management are still early in their penetration curves. Encompass Clamp penetration in CABG, coronary artery bypass grafting, remains low, with volume as the main growth lever. Pain management, especially cryo nerve block, is below 15% penetration, offering a long runway as clinical evidence builds and major cancer centers are targeted.
2. Workflow and Efficiency as Competitive Differentiators
Workflow improvements, especially in hybrid AF therapy, are a strategic focus. Management is investing in hospital handoff processes and clinical consistency to reduce procedure times and enable higher throughput, aiming to make hybrid procedures more scalable and attractive for both surgeons and electrophysiologists.
3. Clinical Trial and Product Pipeline Investment
R&D investment is accelerating, with LEAPS and HEAL-IST trials expanding rapidly and multiple new product launches planned for 2024 and beyond. The next-generation Cryosphere probe, with improved energy efficiency and usability, is expected to anchor pain management momentum as it launches next year.
4. Balanced Operating Leverage
SG&A leverage is emerging, but management is clear that R&D will remain elevated, targeting high-teens to 20% of revenue. This signals a deliberate choice to prioritize long-term innovation over near-term margin maximization, supported by a strong balance sheet.
5. Complementary Positioning Amidst PFA Disruption
Pulse field ablation (PFA) is seen as a market tailwind, not a threat. Management frames AtriCure’s epicardial approach as complementary to endocardial PFA, with no negative impact expected and the potential to drive more hybrid procedures as workflow efficiencies improve.
Key Considerations
AtriCure’s Q3 demonstrates the power of a diversified product portfolio and disciplined execution, yet also raises questions about the sustainability of margin expansion as R&D ramps to support a rich innovation agenda.
Key Considerations:
- Underpenetrated Core Markets: Both open ablation and pain management franchises remain early in adoption, with volume as the key lever for ongoing growth.
- R&D Outpaces SG&A: R&D spend is accelerating ahead of SG&A, reflecting a pipeline-first strategy that may defer margin expansion but supports long-term differentiation.
- Workflow Innovation: Operational focus on workflow and handoff efficiency is critical to unlocking higher hybrid therapy adoption and scaling complex procedures.
- Product Launch Cadence: New launches, including next-gen Cryosphere and upcoming AtriClip Flex Mini, are set to drive future growth, but 2024 will be more about foundational execution than new product contribution.
- Clinical Evidence and Market Access: Major customers, especially in pain management, remain cautious until more clinical evidence is available, slowing penetration into large cancer centers.
Risks
Execution risk remains high as AtriCure seeks to scale in underpenetrated, procedure-based markets where clinical evidence and workflow integration are gating factors. Elevated R&D spend could pressure near-term margins if revenue growth moderates or new products face adoption hurdles. Market access in pain management is contingent on evidence generation and procedural efficiency gains, while competitive dynamics, especially from PFA and other ablation technologies, could shift referral patterns or pricing power.
Forward Outlook
For Q4, AtriCure expects:
- Core franchises (open ablation, appendage management, pain management) to remain primary growth drivers
- Sequential revenue growth resuming as normal seasonality abates
For full-year 2023, management maintained guidance:
- $394 to $396 million in revenue (19–20% YoY growth)
- Adjusted EBITDA of $18–20 million
- Gross margin slightly above 75%
Management emphasized:
- Ongoing R&D investment, especially in LEAPS trial and next-gen product development
- SG&A leverage to persist, but not at the expense of clinical and innovation priorities
Takeaways
AtriCure is executing on a volume-led growth strategy in large, underpenetrated markets, with workflow and clinical trial investment as core differentiators. Margin leverage is emerging, but will be balanced by sustained R&D spend as the company builds a pipeline for long-term growth.
- Volume Drives Growth: Expansion in CABG procedures and pain management adoption are fueling top-line momentum, with substantial market headroom remaining.
- Pipeline-First Approach: Management’s willingness to prioritize R&D over near-term profit signals conviction in clinical and product innovation as the foundation for durable growth.
- 2024 Watchpoints: Investors should monitor progress in workflow efficiency, LEAPS trial enrollment, and the launch cadence of next-generation products to gauge the pace and sustainability of both growth and margin expansion.
Conclusion
AtriCure’s third quarter validates its strategy of targeting large, underpenetrated markets with a diversified product suite and workflow-focused execution. The company’s commitment to clinical evidence and innovation comes at the cost of immediate margin expansion, but positions it for sustained leadership as new products and trials mature.
Industry Read-Through
AtriCure’s results reinforce the opportunity for medtechs targeting complex, underpenetrated procedure markets with workflow and clinical trial differentiation. The focus on R&D and clinical evidence mirrors a broader industry trend toward pipeline-first capital allocation, even as margin leverage becomes a key investor focus. The interplay between endocardial and epicardial ablation, and the rise of PFA, signal that procedural innovation and hybrid approaches will shape the next wave of growth across cardiac and pain management device markets. Companies able to balance near-term profitability with pipeline investment are best positioned to capture expanding patient populations and referral networks.